Drugs / REP 2055
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02646163 | Jan 2009 → Dec 2012 | chronic hepatitis B virus infection | Replicor Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2017-12-12 | Replicor Inc. | Results Replicor announces publication of its in vitro study on NAP activity in HDV replicor.com ↗
early generation NAPs like REP 2055 had a mild ability to block HDV infection |
| 2017-06-28 | Replicor Inc. | Results Replicor announces publication of its studies on the antiviral activity of NAPs in recognized in vitro models of HBV infection replicor.com ↗
These studies demonstrated that early generation NAPs like REP 2055 had an ability to block viral entry only at high concentrations (5-10μM) while later generation (RNA) NAPs like REP 2139 and REP 2165 had negligible entry effect. |
| 2016-06-07 | Replicor Inc. | Results Replicor announces publication of its REP 101 and REP 102 studies demonstrating the therapeutic effect of NAPs and the achievement of functional control off treatment in human patients with chronic hepatitis B infection. replicor.com ↗
In both studies, NAP monotherapy was accompanied by 2 – 7 log reductions of serum HBsAg, 3 – 9 log reductions in serum HBV DNA, seroconversion of HBeAg and the appearance of serum anti-HBsAg antibodies. |
| 2015-11-11 | Replicor Inc. | Results Replicor announces publication of its pre-clinical data on the therapeutic effect of NAPs on hepatitis B virus infection. replicor.com ↗ |
| 2014-10-07 | Replicor Inc. | Results Replicor to present updated clinical trial data with combination treatment using its HBsAg-release inhibitors in patients with chronic hepatitis B infection at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society. replicor.com ↗
Data presented by Replicor during its presentation at the OTS meeting on Oct 15th will demonstrate 1) the unique ability of Replicor’s NAP compounds to completely suppress HBsAg in the blood 2) the effect of HBsAg clearance on dramatically improving the activity of immunotherapy and 3) when used with a full course of Pegasys™, NAP therapy has resulted in the establishment of long term SVR in 80% of patients. |
| 2013-05-14 | Replicor Inc. | Results Replicor presents clinical efficacy and toxicology results in patients with chronic hepatitis B with short term exposure to immunotherapy after REP 2139-ca induced clearance of serum HBsAg. replicor.com ↗
Both REP 2055 and REP 2139-ca were shown to rapidly and effectively remove HBsAg from the blood of patients with HBV infection. |
| 2012-06-22 | Replicor Inc. | Results Replicor to disclose interim REP 2055 / 2139 clinical efficacy data in patients with chronic hepatitis B at the 14th International Symposium of Viral Hepatitis and Liver Disease (ISVHLD 2012) replicor.com ↗
Replicor will present updated clinical efficacy results and metadata analysis of antiviral responses in patients receiving REP 2055 or REP 2139 in an oral presentation on Sunday June 24th, 2012. |
| 2009-12-08 | Replicor Inc. | Results Dr. Allison Jilbert presents preclinical efficacy data for REP 2055 in DHBV infected Pekin ducks replicor.com ↗
Four weeks of daily REP 2055 treatment in Pekin ducks persistently infected with DHBV demonstrated a rapid clearance of serum DHBsAg and detection of substantial anti-DHBsAg antibody titers within 3 weeks of initiation of treatment. |
| 2009-04-16 | Replicor Inc. | Results Replicor publishes data on mechanism of action and pre-clinical efficacy of amphipathic DNA polymers (APs) in HCV infection replicor.com ↗
Pre-clinical assessment of REP 9AC in HCV infected Scid-Hu mice demonstrated that the APs REP AC and REP 2055 were able to provide effective protection from HCV infection and were well tolerated. |
All press releases naming this drug 16 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REP 2055 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02646163 ↗ |
| Route | Intravenous | “REP 2055 is administered once weekly by slow IV infusion” NCT02646163 ↗ |